|dc.description.abstract||Breast cancer is the type most common malignancy in the world, and is the leading cause of death in women in the incidence of more than 1 million people per year. WHO estimated the incidence of breast cancer in women around 8-9 percent. In 2006 breast cancer patients reported in Indonesia ranks second with a 22.5% incidence. The cause of breast cancer is multifactorial, exposure to estrogen is a risk factor in carcinogenesis of breast cancer. Subtypes of breast carcinoma histopathologically divided into invasive ductal carcinoma and invasive lobular carcinoma.
This study is a descriptive study, which was conducted from June to December 2014. The purpose of this study was to determine the clinical characteristics and histopathology of breast cancer patients with estrogen receptor immunohistochemical display (ER) positive in Anatomical Pathology Installation of Haji Adam Malik Hospital / DepartemenPatologi Anatomy Faculty Medicine USU Medan based on histopathological diagnosis, age group, location of tumor, menstrual status, history of pregnancy and childbirth (history parity). The study population is the entire medical records of breast cancer during the years 2011-2013 who meet the inclusion and exclusion criteria, and samples were taken with a total sampling method. The data were then analyzed using statistical test program in accordance with the purpose of research, and the results distribution shown in tabular form.
From the study,it was found that the overall number of cases was 94 sample diagnosed as breast carcinoma. Patients with ER positive breast cancer is more common in the age group 41-50 years (36 cases, 46.1%). Patients with ER positive breast cancers are found in pre-menopausal group (40 cases, 51.6%). Patients with ER positive breast cancer that most are located in the superior and lateral quadrant of the central quadrants, each as much as (9 cases, 29.0%). Patients with ER positive breast cancer with a history of parity is at most a group of patients who have children 1-5 people total (30 cases, 85.7%. Patients with ER positive breast cancer is more common in breast cancer histopathology is at most type of invasive ductal carcinoma (34 cases 75.6%).
The conclusion is, treating ER positive breast cancer is conducted by administering adjuvant therapy using agents that inhibit activation of the estrogen receptor (SERMs) such as tamoxifen or an aromatase inhibitor (AI) as Anastrol. Based on these results, it is expected to be the reading material and a general reference source distribution of breast cancer patients with estrogen receptor display (ER) positive by immunohistochemical examination..||en_US